Altimmune (ALT) Jefferies Global Healthcare Conference 2026 summary

Program updates and clinical progress

• Phase III MASH program for pemvidutide is entering patient enrollment in the second half of the year, with enhanced data from recent EASL presentations supporting its anti-fibrotic effects.

• Two additional phase II trials (AUD and ALD) are ongoing, with the AUD trial expected to read out next quarter and ALD fully enrolled in Q3.

• The company has secured over $500 million in funding, ensuring a runway through 2029 to support MASH phase III and phase II trials for AUD and ALD.

Data highlights and regulatory alignment

• EASL presentations showcased AI-generated imaging and non-invasive testing, consistently demonstrating anti-fibrotic effects of pemvidutide.

• qFibrosis and MASH assist tools are being used in phase III to reduce variability in biopsy readings, with regulatory alignment from FDA and European authorities.

• Phase III design includes both biopsy-proven and NIT-based cohorts, allowing flexibility if regulatory standards evolve.

Market positioning and differentiation

• Pemvidutide aims to differentiate through dual mechanisms: high-quality weight loss and direct liver action, targeting patient segments not well served by GLP monotherapies.

• Lower discontinuation rates and a balanced GLP-1/glucagon ratio are expected to enhance tolerability and efficacy.

• Branding strategy emphasizes liver-targeted action and unique molecular formulation.